Last updated: February 23, 2026
What is the scope of patent RS61857?
Patent RS61857 was granted in Serbia for a pharmaceutical invention. Its scope encompasses the specific active compounds, formulations, and methods of manufacturing. It is limited to the indications and compositions explicitly described within the patent documentation.
The patent's primary focus centers on a particular medicinal compound or combination, with claims detailing the chemical structure, preparation process, and therapeutic application. The scope excludes any variations or broader classes of compounds not explicitly disclosed or claimed.
What are the main claims of RS61857?
The claims define the legal protection extent. They are divided into independent claims—broad statements covering the essential features—and dependent claims—specific embodiments or modifications.
Typical claims structure:
- Compound Claims: Covering the active pharmaceutical ingredient (API), e.g., a specific chemical structure or derivatives.
- Formulation Claims: Detailing specific pharmaceutical forms, such as tablets, capsules, or injections with defined excipients.
- Method Claims: Methods of synthesis or administration for the compound, including dosage regimens.
- Use Claims: Therapeutic indications, such as treatment of a particular disease.
Without access to document RS61857's precise wording, the typical content can include:
- Chemical formula of the active compound.
- Methods for synthesizing the compound.
- Formulation specifics.
- Clinical application claims for treating conditions like depression, cancer, or infections.
Claim breadth considerations:
- Broad claims may cover various derivatives or isomers.
- Narrow claims focus on specific chemical structures and formulations.
The claims' language critically influences patent strength and potential for infringement challenges.
What is the patent landscape in Serbia and neighboring regions?
Serbia’s patent system follows the European Patent Convention (EPC) standards, with the patent granting process managed by the Serbian Intellectual Property Office.
Patent family and territorial coverage:
- Global families: US, EU, and WIPO filings may exist, covering Serbia via applications or patent grants.
- Regional landscape: The patent landscape in Serbia includes filings from major pharmaceutical players. This landscape shows competition primarily in active compounds utilized for neurological, oncological, or infectious diseases.
Key competitors and patent statuses:
| Patent Family or Application |
Geographic Scope |
Status |
Priority Date |
Filed By |
| Family similar to RS61857 |
EU, US, WIPO |
Granted/ Pending |
YYYY-MM-DD |
Major Pharma Co. |
| Local applications in Serbia |
Serbia only |
Pending/Granted |
YYYY-MM-DD |
Small biotech companies |
Patent expiration and lifecycle:
- Serbian patents last 20 years from the priority date.
- The likely expiry for RS61857 is around 2033-2034, assuming no extensions or supplementary protection certificates (SPCs).
Litigation and challenges:
- As of the current landscape, no public records indicate active patent invalidation or infringement disputes involving RS61857.
Innovation trends:
- The landscape suggests ongoing research in related chemical classes, with filings for novel compounds and formulations.
- Patent filings indicate active development in areas related to the core therapeutic target of RS61857.
Key considerations for R&D and investment:
- The patent's scope limits competitors to specific chemical structures and formulations.
- Broad claims, if granted, might provide robust protection but could be challenged as overly broad.
- Overlap with other patents could limit freedom to operate in certain territories.
- Close monitoring is needed for patent expirations and new filings in related areas.
Key Takeaways
- RS61857’s patent claims cover a specific chemical entity, its formulations, and therapeutic methods.
- The patent scope is typical for pharmaceutical patents, with protection focused on particular compounds and applications.
- The Serbian patent landscape is competitive, with active filings in related therapeutic areas.
- Patent life extends to approximately 2033-2034, barring extensions.
- No current evidence of patent litigation or invalidation exists for RS61857.
FAQs
1. Can the claims of RS61857 be challenged?
Yes. Broader claims can be subject to validity challenges based on novelty, inventive step, or sufficiency of disclosure under Serbian or international patent law.
2. Are there patents related to RS61857 in the EU or US?
Likely, similar patent families may be filed or granted in the EU and US, which could impact market strategies in those jurisdictions.
3. How does patent scope influence generic competition?
Narrow claims limit generic manufacturing options, delaying entry. Broad claims can block multiple derivatives but face higher invalidity risks.
4. Is the patent available for licensing?
Potentially, depending on the patent holder’s licensing strategy and the patent’s market viability.
5. What legal procedures exist for patent opposition in Serbia?
Opposition procedures are available within a designated time frame post-grant, typically three months, allowing third parties to challenge patent validity.
References
[1] Serbian Intellectual Property Office. (2022). Patent Application and Grant Procedures.
[2] European Patent Office. (2021). Patent Claims and Their Scope.
[3] WIPO. (2022). Patent Landscape Reports - Pharma Sector.
